Alpha Thalassemia Epidemiology Forecast Insight

DelveInsight’s ‘Alpha Thalassemia - Epidemiology Forecast–2030’ report delivers an in-depth understanding of the disease, historical and forecasted Alpha Thalassemia epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, Spain, Italy, France, and United Kingdom)
  • Japan

Study Period: 2018–2030

Alpha Thalassemia Understanding

Thalassemias are a group of blood disorders that affect the way the body makes hemoglobin. Alpha (α) thalassemia refers specifically to the abnormal or absent manufacturing of alpha-globin chains. These are associated with more than 15 different genetic mutations

 

The condition ranges from asymptomatic to severe. Sometimes, a person can be a carrier (silent α-thalassemia) with no sign of disease. Others may have very mild disease, known as having Alpha Thalassemia trait. Patients with Alpha Thalassemia traits require no treatment or long-term monitoring. While patients with α-thalassemia minor have lifelong mild anemia. Those with more moderate to severe cases may require blood transfusions or chelation therapy.

 

Complications of Alpha Thalassemia include excess iron, bone deformities, and broken bones, enlarged spleen, infections, and slower growth rates. The signs and symptoms of Alpha Thalassemia vary depending on the type that a child has and how severe it is. Children with Alpha Thalassemia trait and those who are silent carriers have no symptoms at all. Some of the more common symptoms of Alpha Thalassemia include fatigue, weakness, or shortness of breath, a pale appearance or yellow color to the skin (jaundice), irritability, and others.

 

Alpha Thalassemia Diagnosis

In order to identify fetuses with hemoglobin Bart’s hydrops fetalis and decrease the hazards to mothers, prenatal diagnostics is essential. The presence of hypochromic microcytic red cells in both parents, along with a normal hemoglobin A2 level, usually leads to the consideration of such a diagnosis; this combination would rule out β-thalassemia, which is characterized by an elevated hemoglobin A2 level. An iron deficiency must also be ruled out. The hematologic evaluation is followed by confirmation of the presence of α0-thalassemia in the parents when facilities for fast DNA diagnosis are available. The fetal diagnosis is usually made early in pregnancy utilizing chorionic-villus sampling. However, fetal anemia may also be diagnosed later during gestation by quantitation of the peak systolic velocity in the middle cerebral artery.

 

In the United States, infants may be diagnosed with α-thalassemia through newborn screening. Newborn screening is a public health program that mandates the evaluation of newborn infants for various treatable disorders, but not readily apparent at birth. Each state’s newborn screening program (and the specific disorders tested) is different, and further testing is required to determine the exact type of α-thalassemia present.

 

Initial laboratory testing should include a complete blood count with red cell indices, HPLC or Hb electrophoresis, and eventually α/β-globin chain synthesis ratio measurement. The latter procedure, however, is sometimes bypassed by DNA analysis as a less complicated method to diagnose α- thalassemia.

Alpha Thalassemia Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by diagnosed prevalent cases, diagnosed prevalent cases of Alpha Thalassemia based on transfusion requirement, and treatment eligible cases of Alpha Thalassemia in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan market from 2018 to 2030.

 

Key Findings

This section provides glimpse of the Alpha Thalassemia epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

  • The total diagnosed prevalent cases of α-thalassemia in the 7MM range from 3,973 in 2020 growing at a CAGR of 1.3% during the study period (2018–2030).
  • Epidemiology assessed for the condition showed that the US, in 2020, accounted for approximately 1,415 diagnosed prevalent cases of α-thalassemia.
  • Among the EU-5 countries in 2020, Italy had the highest diagnosed prevalent cases of α-thalassemia with 1,003 cases, followed by Spain (410) and Germany (302). In contrast, France had the lowest cases (196) in 2020.
  • Japan accounted for 362 diagnosed prevalent α-thalassemia cases in 2020.
  • In the United States, in 2020, the proportion of non-transfusion-dependent thalassemia (NTDT) and transfusion-dependent thalassemia (TDT) cases were 859 and 556, respectively.
  • As per the analysis, a higher percentage of non-transfusion-dependent thalassemia (NTDT) was observed in the EU-5 compared to transfusion-dependent thalassemia (TDT) in 2020.
  • Among the EU5 countries, Italy accounted for the highest cases of NTDT cases in 2020, whereas France accounted for the lowest cases of NTDT cases in 2020.
  • Japan accounted for approximately 362 treatment eligible cases of α-thalassemia in 2020.
  • The United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan – Alpha Thalassemia Epidemiology

Scope of the Report

  • The report covers the descriptive overview of Alpha Thalassemia, explaining its causes, signs and symptoms, pathophysiology.
  • The report provides insight into the historical and forecasted patient pool covering the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Alpha Thalassemia.
  • The report provides the segmentation of the disease epidemiology for the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Report Highlights

  • Ten Year Forecast of Alpha Thalassemia
  • The United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan Coverage
  • Total treatment eligible population of Alpha Thalassemia.

Key Questions Answered

  • What is the disease risk, burden and unmet needs of Alpha Thalassemia?
  • What is the historical Alpha Thalassemia patient pool in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan?
  • What would be the forecasted patient pool of Alpha Thalassemia at the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan level?
  • What will be the growth opportunities in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan with respect to the patient population pertaining to Alpha Thalassemia?
  • At what CAGR the population is expected to grow in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan during the forecast period (2021–2030)?

Reasons to buy

The Alpha Thalassemia report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan Alpha Thalassemia market.
  • Quantify patient share distribution in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan for Alpha Thalassemia.
  • The Alpha Thalassemia epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Alpha Thalassemia epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Executive Summary of Alpha Thalassemia

4. Key Events

5. Epidemiology Forecast Methodology

6. Disease Background and Overview

6.1. Signs and Symptoms

6.2. Causes

6.3. Clinical Manifestations

6.4. Pathophysiology

6.5. Diagnosis

6.5.1. Hematology

6.5.2. Alpha/beta-globin chain synthesis

6.5.3. Molecular analysis

6.6. Differential diagnosis and Genetic Counseling

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. Total Diagnosed Prevalent Population of Alpha Thalassemia in the 7MM

7.3. Diagnosed Prevalent Cases of Alpha Thalassemia based on Transfusion Requirement in the 7MM

7.4. Treatment Eligible Cases of Alpha Thalassemia in the 7MM

7.5. Assumptions and Rationale

7.6. The United States

7.6.1. Total Diagnosed Prevalent Population of Alpha Thalassemia in the United States

7.6.2. Diagnosed Prevalent Cases of Alpha Thalassemia based on Transfusion Requirement in the United States

7.6.3. Treatment Eligible Cases of Alpha Thalassemia in the United States (2018–2030) in the United States

7.7. EU5

7.7.1. Total Diagnosed Prevalent Population of Alpha Thalassemia in EU5

7.7.2. Diagnosed Prevalent Cases of Alpha Thalassemia based on Transfusion Requirement in EU5

7.7.3. Treatment eligible Cases of Alpha Thalassemia in EU5

7.8. Japan

7.8.1. Total Diagnosed Prevalent Population of Alpha Thalassemia in Japan

7.8.2. Diagnosed Prevalent Cases of Alpha Thalassemia based on Transfusion Requirement in Japan

7.8.3. Treatment eligible Cases of Alpha Thalassemia in Japan

8. Appendix

9. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Table

Table 1: Summary of Alpha Thalassemia Epidemiology (2018–2030)

Table 2: Key Events

Table 3: Red Blood Cell Indices in Individuals with Hb Bart Syndrome and HbH Disease

Table 4: Genotype-phenotype associations in α-thalassemia

Table 5: Total Diagnosed Prevalent Population of Alpha Thalassemia in the 7MM (2018–2030)

Table 6: Diagnosed Prevalent Cases of Alpha Thalassemia based on Transfusion Requirement in the 7MM (2018–2030)

Table 7: Treatment Eligible Cases of Alpha Thalassemia in the 7MM (2018–2030)

Table 8: Total Diagnosed Prevalent Population of Alpha Thalassemia in the US (2018–2030)

Table 9: Diagnosed Prevalent Cases of Alpha Thalassemia based on Transfusion Requirement in the US (2018–2030)

Table 10: Treatment Eligible Cases of Alpha Thalassemia in the United States (2018–2030)

Table 11: Total Diagnosed Prevalent Population of Alpha Thalassemia in EU5 (2018–2030)

Table 12: Diagnosed Prevalent Cases of Alpha Thalassemia based on Transfusion Requirement in EU5 (2018–2030)

Table 13: Treatment Eligible Cases of Alpha Thalassemia in EU5 (2018–2030)

Table 14: Total Diagnosed Prevalent Population of Alpha Thalassemia in the Japan (2018–2030)

Table 15: Diagnosed Prevalent Cases of Alpha Thalassemia based on Transfusion Requirement in Japan (2018–2030)

List of Figures

Figure 1: Phenotype–Genotype Relationship in α-thalassemia

Figure 2: The Clinical Spectrum of Thalassemia Syndromes Based on Their Requirement of Regular Blood Transfusions into NTDT and TDT

Figure 3: Total Diagnosed Prevalent Population of Alpha Thalassemia in the 7MM (2018–2030)

Figure 4: Diagnosed Prevalent Cases of Alpha Thalassemia based on Transfusion Requirement in the 7MM (2018–2030)

Figure 5: Treatment Eligible Cases of Alpha Thalassemia in the 7MM (2018–2030)

Figure 6: Total Diagnosed Prevalent Population of Alpha Thalassemia in the US (2018–2030)

Figure 7: Diagnosed Prevalent Cases of Alpha Thalassemia based on Transfusion Requirement in the US (2018–2030)

Figure 8: Treatment Eligible Cases of Alpha Thalassemia in the United States (2018–2030)

Figure 9: Total Diagnosed Prevalent Population of Alpha Thalassemia in EU5 (2018–2030)

Figure 10: Diagnosed Prevalent Cases of Alpha Thalassemia based on Transfusion Requirement in EU5 (2018–2030)

Figure 11: Treatment Eligible Cases of Alpha Thalassemia in EU5 (2018–2030)

Figure 12: Total Diagnosed Prevalent Population of Alpha Thalassemia in Japan (2018–2030)

Figure 13: Diagnosed Prevalent Cases of Alpha Thalassemia based on Transfusion Requirement in Japan (2018–2030)

Figure 14: Treatment Eligible Cases of Alpha Thalassemia in Japan (2018–2030)

Forward to Friend

Need A Quote